Kesimpta and Intestinal obstruction - a phase IV clinical study of FDA data

Summary:

Intestinal obstruction is reported as a side effect among people who take Kesimpta (ofatumumab), especially for people who are female, 50-59 old, also take Vitamins, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Intestinal obstruction when taking Kesimpta. It is created by eHealthMe based on reports of 36,581 people who have side effects when taking Kesimpta from the FDA, and is updated regularly.

What is Kesimpta?

Kesimpta has active ingredients of ofatumumab. eHealthMe is studying from 36,592 Kesimpta users. Check the latest studies of Kesimpta.

What is Intestinal obstruction?

Intestinal obstruction is found to be associated with 1,886 drugs and 2,613 conditions by eHealthMe. Check the latest studies of Intestinal obstruction.

On Jul, 09, 2026

36,581 people reported to have side effects when taking Kesimpta.
Among them, 16 people (0.04%) have Intestinal obstruction.

Could Kesimpta cause Intestinal obstruction?

Among these 16 people:

What is the gender of people who have Intestinal obstruction when taking Kesimpta? *

female: 93.33 %
male: 6.67 %

What is the age of people who have Intestinal obstruction when taking Kesimpta? *

What are other drugs people take besides Kesimpta? *

What are other side effects people have besides Intestinal obstruction? *

Constipation: 4 people, 25.00%
Itching: 4 people, 25.00%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 18.75%
White Blood Cell Count Decreased: 2 people, 12.50%
Pain In Jaw: 2 people, 12.50%
Blood Sodium Decreased: 2 people, 12.50%
Clavicle Fracture: 2 people, 12.50%
Fall: 2 people, 12.50%
Headache (pain in head): 2 people, 12.50%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 12.50%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 8 people, 50.00%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 25.00%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 2 people, 12.50%
Clinically Isolated Syndrome (individual's first neurological episode, caused by inflammation or demyelination of nerve tissue): 2 people, 12.50%
Hepatitis B: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Kesimpta and have Intestinal obstruction?

- Check whether Intestinal obstruction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Kesimpta:

Kesimpta (36,592 reports)

Browse all side effects of Kesimpta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intestinal obstruction:

Intestinal obstruction (1,886 drugs)

Browse all the conditions that are associated with Intestinal obstruction:

Intestinal obstruction (2,613 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ofatumumab (the active ingredients of Kesimpta) and Kesimpta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.